{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:20:32Z","timestamp":1789546832218,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Institute of Medical Sciences, Kangwon National University","award":["2024"],"award-info":[{"award-number":["2024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-025-05259-z","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T14:31:32Z","timestamp":1737469892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Structural comparison of human and Plasmodium proteasome \u03b25 subunits: informing selective inhibitor design for anti-malaria agents"],"prefix":"10.1186","volume":"24","author":[{"given":"Muhammad","family":"Yasir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Taek","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjoo","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"5259_CR1","unstructured":"WHO. Malaria eradication: benefits, future scenarios and feasibility: a report of the Strategic Advisory Group on Malaria Eradication. Geneva, World Health Organization, 2020. https:\/\/iris.who.int\/bitstream\/handle\/10665\/331795\/9789240003675-eng.pdf?sequence=1"},{"key":"5259_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12936-017-1787-y","volume":"16","author":"BE Barber","year":"2017","unstructured":"Barber BE, Rajahram GS, Grigg MJ, William T, Anstey NM. World Malaria Report: time to acknowledge Plasmodium knowlesi malaria. Malar J. 2017;16:135.","journal-title":"Malar J"},{"key":"5259_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"5259_CR4","unstructured":"Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al."},{"key":"5259_CR5","doi-asserted-by":"crossref","unstructured":"Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960\u20136.","DOI":"10.1016\/S0140-6736(12)60484-X"},{"key":"5259_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1473-3099(12)70181-0","volume":"12","author":"C Amaratunga","year":"2012","unstructured":"Amaratunga C, Sreng S, Suon S, Phelps ES, Stepniewska K, Lim P, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012;12:851\u20138.","journal-title":"Lancet Infect Dis"},{"key":"5259_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1039\/D0NP00079E","volume":"38","author":"H-N Lyu","year":"2021","unstructured":"Lyu H-N, Ma N, Meng Y, Zhang X, Wong Y-K, Xu C, et al. Study towards improving artemisinin-based combination therapies. Nat Prod Rep. 2021;38:1243\u201350.","journal-title":"Nat Prod Rep"},{"key":"5259_CR8","doi-asserted-by":"crossref","unstructured":"Nguyen TD, Gao B, Amaratunga C, Dhorda M, Tran TN-A, White NJ, et al. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat Commun. 2023;14:4568.","DOI":"10.1038\/s41467-023-39914-3"},{"key":"5259_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin\u2013piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357\u201365.","journal-title":"Lancet Infect Dis"},{"key":"5259_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","volume":"15","author":"MD Spring","year":"2015","unstructured":"Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683\u201391.","journal-title":"Lancet Infect Dis"},{"key":"5259_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/QCO.0000000000000199","volume":"28","author":"RMJ Fairhurst","year":"2015","unstructured":"Fairhurst RMJ. Understanding artemisinin-resistant malaria: what a difference a year makes. Curr Opin Infect Dis. 2015;28:417.","journal-title":"Curr Opin Infect Dis"},{"key":"5259_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","volume":"71","author":"TA Thibaudeau","year":"2019","unstructured":"Thibaudeau TA, Smith DM. A practical review of proteasome pharmacology. Pharmacol Rev. 2019;71:170\u201397.","journal-title":"Pharmacol Rev"},{"key":"5259_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/iub.2586","volume":"74","author":"M Kapetanou","year":"2022","unstructured":"Kapetanou M, Athanasopoulou S, Gonos ES. Transcriptional regulatory networks of the proteasome in mammalian systems. IUBMB Life. 2022;74:41\u201352.","journal-title":"IUBMB Life"},{"key":"5259_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.chembiol.2021.04.003","volume":"28","author":"F T\u00fcrker","year":"2021","unstructured":"T\u00fcrker F, Cook EK, Margolis SS. The proteasome and its role in the nervous system. Cell Chem Biol. 2021;28:903\u201317.","journal-title":"Cell Chem Biol"},{"key":"5259_CR15","first-page":"421","volume":"11","author":"J Abi Habib","year":"2022","unstructured":"Abi Habib J, Lesenfants J, Vigneron N, Van den Eynde BJ. Functional differences between proteasome subtypes Cells. 2022;11:421.","journal-title":"Functional differences between proteasome subtypes Cells"},{"key":"5259_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107526","volume":"211","author":"X Wang","year":"2020","unstructured":"Wang X, Meul T, Meiners S. Therapeutics: Exploring the proteasome system: a novel concept of proteasome inhibition and regulation. Pharmacol Ther. 2020;211: 107526.","journal-title":"Pharmacol Ther"},{"key":"5259_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.arcmed.2020.09.007","volume":"52","author":"I Fern\u00e1ndez-Cruz","year":"2021","unstructured":"Fern\u00e1ndez-Cruz I, Reynaud E. Proteasome subunits involved in neurodegenerative diseases. Arch Med Res. 2021;52:1\u201314.","journal-title":"Arch Med Res"},{"key":"5259_CR18","doi-asserted-by":"publisher","first-page":"7608","DOI":"10.3390\/ijms21207608","volume":"21","author":"P Karabowicz","year":"2020","unstructured":"Karabowicz P, Wro\u0144ski A, Ostrowska H, Waeg G, Zarkovic N. Skrzydlewska E Reduced proteasome activity and enhanced autophagy in blood cells of psoriatic patients. Int J Mol Sci. 2020;21:7608.","journal-title":"Int J Mol Sci"},{"key":"5259_CR19","doi-asserted-by":"crossref","unstructured":"Kapoor N, Ghorai SM. Role of naturally occurring lead compounds as potential drug targets against malaria. In: Kesharwani RK, Mishra K (eds.). Biotechnology in the Modern Medicinal System. Apple Academic Press. 2021.","DOI":"10.1201\/9781003129783-1"},{"key":"5259_CR20","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1128\/AAC.00742-12","volume":"57","author":"S Tschan","year":"2013","unstructured":"Tschan S, Brouwer AJ, Werkhoven PR, Jonker AM, Wagner L, Knittel S, et al. Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors. Antimicrob Agents Chemother. 2013;57:3576\u201384.","journal-title":"Antimicrob Agents Chemother"},{"key":"5259_CR21","doi-asserted-by":"publisher","first-page":"E6863","DOI":"10.1073\/pnas.1806109115","volume":"115","author":"LA Kirkman","year":"2018","unstructured":"Kirkman LA, Zhan W, Visone J, Dziedziech A, Singh PK, Fan H, et al. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance. Proc Natl Acad Sci USA. 2018;115:E6863\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5259_CR22","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.16144","volume":"180","author":"JF Armstrong","year":"2023","unstructured":"Armstrong JF, Campo B, Alexander SP, Arendse LB, Cheng X, Davenport AP, et al. Advances in malaria pharmacology and the online guide to malaria pharmacology: IUPHAR review 38. Br J Pharmacol. 2023;180:1899\u2013929.","journal-title":"Br J Pharmacol"},{"key":"5259_CR23","doi-asserted-by":"crossref","unstructured":"Simwela NV, Stokes BH, Aghabi D, Bogyo M, Fidock DA, Waters AP. Plasmodium berghei k13 mutations mediate in vivo artemisinin resistance that is reversed by proteasome inhibition. mBio. 2020;11:e02312\u201320.","DOI":"10.1128\/mBio.02312-20"},{"key":"5259_CR24","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.1002\/ange.202015845","volume":"133","author":"W Zhan","year":"2021","unstructured":"Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, et al. Development of a highly selective Plasmodium falciparum proteasome inhibitor with anti-malaria activity in humanized mice. Angew Chem Int Ed Engl. 2021;133:9365\u20139.","journal-title":"Angew Chem Int Ed Engl"},{"key":"5259_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002132","volume":"13","author":"C Dogovski","year":"2015","unstructured":"Dogovski C, Xie SC, Burgio G, Bridgford J, Mok S, McCaw JM, et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol. 2015;13: e1002132.","journal-title":"PLoS Biol"},{"key":"5259_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nature16936","volume":"530","author":"H Li","year":"2016","unstructured":"Li H, O\u2019Donoghue AJ, van der Linden WA, Xie SC, Yoo E, Foe IT, et al. Structure- and function-based design of Plasmodium-selective proteasome inhibitors. Nature. 2016;530:233\u20136.","journal-title":"Nature"},{"key":"5259_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1080\/14728222.2019.1685981","volume":"23","author":"SC Xie","year":"2019","unstructured":"Xie SC, Dick LR, Gould A, Brand S, Tilley L. The proteasome as a target for protozoan parasites. Expert Opin Ther Targets. 2019;23:903\u201314.","journal-title":"Expert Opin Ther Targets"},{"key":"5259_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","volume":"22","author":"JL Siqueira-Neto","year":"2023","unstructured":"Siqueira-Neto JL, Wicht KJ, Chibale K, Burrows JN, Fidock DA, Winzeler EA. Antimalarial drug discovery: progress and approaches. Nat Rev Drug Discov. 2023;22:807\u201326.","journal-title":"Nat Rev Drug Discov"},{"key":"5259_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2107213118","volume":"118","author":"SC Xie","year":"2021","unstructured":"Xie SC, Metcalfe RD, Mizutani H, Puhalovich T, Hanssen E, Morton CJ, et al. Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome. Proc Natl Acad Sci USA. 2021;118: e2107213118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5259_CR30","unstructured":"Studio, D. Discovery studio. 2008. Available online: https:\/\/scholar.google.com\/scholar?hl=en&q=Discovery%0AStudio%2C+2008."},{"key":"5259_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera\u2014a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605\u201312.","journal-title":"J Comput Chem"},{"key":"5259_CR32","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1093\/nar\/gkg565","volume":"31","author":"L Willard","year":"2003","unstructured":"Willard L, Ranjan A, Zhang H, Monzavi H, Boyko RF, Sykes BD, et al. VADAR: a web server for quantitative evaluation of protein structure quality. Nucleic Acids Res. 2003;31:3316\u20139.","journal-title":"Nucleic Acids Res"},{"key":"5259_CR33","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem. 2008;29:1859\u201365.","journal-title":"J Comput Chem"},{"key":"5259_CR34","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1021\/acs.jcim.3c01090","volume":"63","author":"M Yasir","year":"2023","unstructured":"Yasir M, Park J, Han E-T, Park WS, Han J-H, Kwon Y-S, et al. Machine learning-based drug repositioning of novel Janus kinase 2 inhibitors utilizing molecular docking and molecular dynamic simulation. J Chem Inf Model. 2023;63:6487\u2013500.","journal-title":"J Chem Inf Model"},{"key":"5259_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282304","volume":"18","author":"Z Ataei","year":"2023","unstructured":"Ataei Z, Nouri Z, Tavakoli F, Pourreza MR, Narrei S, Tabatabaiefar MA. Novel in-frame duplication variant characterization in late infantile metachromatic leukodystrophy using whole-exome sequencing and molecular dynamics simulation. PLoS ONE. 2023;18: e0282304.","journal-title":"PLoS ONE"},{"key":"5259_CR36","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1021\/acs.jpcb.0c04435","volume":"124","author":"A Saha","year":"2020","unstructured":"Saha A, Oanca G, Mondal D, Warshel A. Exploring the proteolysis mechanism of the proteasomes. J Phys Chem B. 2020;124:5626\u201335.","journal-title":"J Phys Chem B"},{"key":"5259_CR37","doi-asserted-by":"publisher","first-page":"11424","DOI":"10.1021\/jacs.8b06656","volume":"140","author":"E Yoo","year":"2018","unstructured":"Yoo E, Stokes BH, de Jong H, Vanaerschot M, Kumar T, Lawrence N, et al. Defining the determinants of specificity of Plasmodium proteasome inhibitors. J Am Chem Soc. 2018;140:11424\u201337.","journal-title":"J Am Chem Soc"},{"key":"5259_CR38","doi-asserted-by":"publisher","first-page":"6721","DOI":"10.1021\/acs.jmedchem.7b00671","volume":"60","author":"GM LaMonte","year":"2017","unstructured":"LaMonte GM, Almaliti J, Bibo-Verdugo B, Keller L, Zou BY, Yang J, et al. Development of a potent inhibitor of the Plasmodium proteasome with reduced mammalian toxicity. J Med Chem. 2017;60:6721\u201332.","journal-title":"J Med Chem"},{"key":"5259_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/molecules28010414","volume":"28","author":"M Yasir","year":"2023","unstructured":"Yasir M, Park J, Han E-T, Park WS, Han J-H, Kwon Y-S, et al. Exploration of flavonoids as lead compounds against ewing sarcoma through molecular docking, pharmacogenomics analysis, and molecular dynamics simulations. Molecules. 2023;28:414.","journal-title":"Molecules"},{"key":"5259_CR40","doi-asserted-by":"publisher","first-page":"34160","DOI":"10.1021\/acsomega.3c05425","volume":"8","author":"M Yasir","year":"2023","unstructured":"Yasir M, Park J, Han E-T, Park WS, Han J-H, Kwon Y-S, et al. Vismodegib identified as a novel COX-2 inhibitor via deep-learning-based drug repositioning and molecular docking analysis. ACS Omega. 2023;8:34160\u201370.","journal-title":"ACS Omega"},{"key":"5259_CR41","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.3390\/ijms20215326","volume":"20","author":"RA Guedes","year":"2019","unstructured":"Guedes RA, Aniceto N, Andrade MAP, Salvador JAR, Guedes RC. Chemical patterns of proteasome inhibitors: lessons learned from two decades of drug design. Int J Mol Sci. 2019;20:5326.","journal-title":"Int J Mol Sci"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05259-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-025-05259-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-025-05259-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T02:08:48Z","timestamp":1737511728000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-025-05259-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5259"],"URL":"https:\/\/doi.org\/10.1186\/s12936-025-05259-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}